E-Vent: Electrical muscle stimulation in mechanical Ventilation

The effects of electrical muscle stimulation on muscle mass, strength and function in patients receiving mechanical ventilation: a randomised controlled, single-blind feasibility study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN35179428

Enrollment

Registered

2013-01-31

Start date

2012-10-01

Completion date

Unknown

Last updated

2019-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically ill patients receiving prolonged periods of mechanical ventilation Respiratory Critically ill patients receiving prolonged periods of mechanical ventilation

Interventions

Electrical muscle stimulation twice daily 30 minute sessions of electrical muscle stimulation to biceps and quadriceps, for duration of critical care stay.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The target population is critically ill patients expected to receive prolonged mechanical ventilation (MV) 2. 18 years or older, male and female 3. Expected to receive MV for > 72 hour

Exclusion criteria

Exclusion criteria: 1. Body mass index 35kg/m² 2. Pre-existing neuromuscular conditions affecting peripheral nervous system 3. Pacemaker or implanted cardiac defibrillator 4. Skin lesions making electrode placement impossible 5. Current upper and/ or lower limb fractures 6. Current pregnancy 7. Unable to walk or perform transfers prior to acute illness 8. Chronic renal disease 9. Chronic liver failure (Child Pugh score >3) 10. Irreversible disease with 10mg 12. Uncontrolled / difficult to control epilepsy

Design outcomes

Primary

Measure	Time frame
Ultrasound quadriceps muscle layer thickness; Timepoint(s): Baseline, study days 4,7 and every 3 days, ICU discharge, hospital discharge	—

Secondary

Measure	Time frame
1. US (composite score: mid thigh, forearm and upper arm; rectus femoris cross sectional area ) 2. Manual muscle Testing individual and composite muscle strength scores 3. Handgrip strength 4. Hand held dynamometry limb muscle strength 5. Barthel Index (BI) physical function score 6. Six-minute walk test 7. SF-36 (v2) health related quality of life questionnaire 8. Surrogate muscle biomarkers (serum c-reactive protein (CRP), plasma creatine kinase (PCK), plasma 3 methyl histidine (P3-MH), urinary creatine kinase (UCK) and 3 methyl histidine (U3- MH) 9. MV days 10. ICU, hospital and 90 day mortality 11. ICU and hospital length of stay (LOS) 12. Hospital resource use at discharge	—

Measure

Time frame

1. US (composite score: mid thigh, forearm and upper arm; rectus femoris cross sectional area ) 2. Manual muscle Testing individual and composite muscle strength scores 3. Handgrip strength 4. Hand held dynamometry limb muscle strength 5. Barthel Index (BI) physical function score 6. Six-minute walk test 7. SF-36 (v2) health related quality of life questionnaire 8. Surrogate muscle biomarkers (serum c-reactive protein (CRP), plasma creatine kinase (PCK), plasma 3 methyl histidine (P3-MH), urinary creatine kinase (UCK) and 3 methyl histidine (U3- MH) 9. MV days 10. ICU, hospital and 90 day mortality 11. ICU and hospital length of stay (LOS) 12. Hospital resource use at discharge

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026